Innovative directions in oncology drug development: Charting a course through the complexities.

### About the Envision Pharma Group Oncology Consultancy

The Envision Pharma Group Oncology Consultancy is a leading provider of insights and analysis on the global oncology industry. Our team of experts includes senior contributors from a diverse range of disciplines, including pharmacology, biotechnology, and oncology.

**Services:**
- Industry Analysis
- Market Research
- Business Development
- Regulatory Affairs
- Clinical Trials

**Expertise:**
- Drug Development
- Clinical Research
- Regulatory Compliance
- Market Access

**Contact:**
Envision Pharma Group Oncology Consultancy
OncologyCoreGroup@envisionpharma.com

---

**HALLMARKS OF INNOVATION**

**Quick Navigation**

- Immunotherapy
- Targeted Therapy
- Antibody-Drug Conjugates
- Radioligand Therapy
- Biomarkers

---

**Immunotherapy**

**Current State**
- Limited by challenges in defining and evaluating immunogenicity
- Ongoing need to consider factors that impact immune response

**What to Look For**
- Clear demonstration of efficacy in clinical trials
- Identification of biomarkers for selecting patients
- Potential to target specific immune cells

**Advances on the Horizon**
- Novel immune agonist MOAs
- Targeted approaches to NK cells
- CAR-Ts for solid tumors

---

**Targeted Therapy**

**Current State**
- Utilizes knowledge of molecular pathways and mechanisms
- Ongoing emphasis on precision medicine

**What to Look For**
- Understanding of tumor biology
- Identification of biomarkers for patient selection

**Advances on the Horizon**
- Targeting of novel oncogenic drivers
- Personalized strategies

---

**Antibody-Drug Conjugates**

**Current State**
- Rising interest in new ADC technologies

**What to Look For**
- Diverse mechanism of action
- Identifiable biomarkers for patient selection

**Advances on the Horizon**
- Improved tolerability
- Novel targets

---

**Radioligand Therapy**

**Current State**
- Demand for radioligand therapy is increasing

**What to Look For**
- Clear indications for use
- Potential for broad application

**Advances on the Horizon**
- Novel targets
- Improved radioligand designs

---

**Biomarkers**

**Current State**
- Biomarkers are widely used in oncology

**What to Look For**
- Clearly defined niche applications
- Value and a reproducible assay

**Advances on the Horizon**
- Future novel ADC design elements
- Novel immune agonist MOAs or CAR-Ts

---

**About the Envision Pharma Group Oncology Consultancy**

Envision Pharma Group is a leading provider of market intelligence and analysis for the global healthcare industry. Our team of experts includes senior contributors from a diverse range of disciplines, including pharmacology, biotechnology, and oncology.

**Contact:**
Envision Pharma Group Oncology Consultancy
OncologyCoreGroup@envisionpharma.com